Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 10/20 | 0.39 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CMA1 | P23946 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30314568 | 1.00 | P2RX7 (0.39) | P2RX7C5AR1NPC1GLARAB9A | |
| SCHEMBL30314141 | 0.93 | C5AR1 (0.43) | P2RX7C5AR1NPC1GLARAB9A | |
| SCHEMBL20548469 | 0.93 | C5AR1 (0.43) | P2RX7C5AR1NPC1GLARAB9A | |
| SCHEMBL20548552 | 0.92 | MAPT (0.38) | P2RX7C5AR1 | |
| SCHEMBL30314279 | 0.92 | MAPT (0.38) | P2RX7C5AR1 | |
| SCHEMBL20548435 | 0.89 | NPC1 (0.40) | NPC1GLARAB9AL3MBTL1MEN1 | |
| SCHEMBL30314537 | 0.89 | NPC1 (0.40) | NPC1GLARAB9AL3MBTL1MEN1 | |
| SCHEMBL20548655 | 0.86 | KMT2A (0.47) | NPC1GLARAB9AL3MBTL1MEN1 | |
| SCHEMBL20548650 | 0.86 | L3MBTL1 (0.43) | NPC1GLARAB9AL3MBTL1MEN1 | |
| SCHEMBL30314366 | 0.86 | L3MBTL1 (0.43) | NPC1GLARAB9AL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11623919-B2 | Heterocyclic P2X7 antagonists | BREYE THERAPEUTICS APS (DK) | 2023-04-11 | — | — | US | claimed |
| US-20200055831-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | BREYE THERAPEUTICS APS (DK) | 2020-02-20 | — | — | US | claimed |
| EP-3398941-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | AXXAM S.p.A. (IT) | 2018-11-07 | — | — | EP | claimed |
| US-11623919-B2 | Heterocyclic P2X7 antagonists | BREYE THERAPEUTICS APS (DK) | 2023-04-11 | — | — | US | disclosed |
| US-20200055831-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | BREYE THERAPEUTICS APS (DK) | 2020-02-20 | — | — | US | disclosed |
| US-20200055831-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | BREYE THERAPEUTICS APS (DK) | 2020-02-20 | — | — | US | disclosed |
| EP-3398941-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | AXXAM S.p.A. (IT) | 2018-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055831-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | P2RY1, P2RX1, P2RX3 | P2RX7 4/4885C5AR1 224/4885NPC1 468/4885 |
| US-11623919-B2 | Heterocyclic P2X7 antagonists | P2RY1, P2RX1, P2RX3 | P2RX7 4/4885C5AR1 224/4885NPC1 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.